跳至主要内容
临床试验/NCT00295776
NCT00295776终止2 期

Lamictal in the Treatment of Post-Herpetic Neuralgia-A Safety, Efficacy,Randomized, Double Blind, Placebo Controlled, Cross-Over Study

George Washington University2 个研究点 分布在 1 个国家开始时间: 2005年2月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
终止
试验地点
2

研究概览

简要总结

To assess the efficacy of Lamictal for the treatment of pain and reduction of allodynia in patients with post herpetic neuralgia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
盲法
Double

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All patients will be over the age of 18,
  • Need to have a diagnosis of Post-Herpetic Neuralgia,
  • Minimum of 4 on the Likert Pain Scale,
  • If currently taking TCA and/or Gabapentin, need to have been on stable dose for minimum of 4 weeks

排除标准

  • Currently on any antiepileptic drugs (AED), except for Gabapentin.
  • Currently taking opioid or unwilling to washout prior to the study,
  • Pregnant and lactating,
  • Have active severe systemic disease,
  • History of Stevens-Johnson syndrome or TEN,
  • Clinically significant abnormal lab values,
  • Known drug allergy to Lamictal,
  • Patients on Fibrates (Tricor and Lopid),
  • History of major psychiatric disturbance and substance abuse.
  • Valproate due to increase chances of severe rash,
  • Lidocaine Patch,
  • Use of hormonal contraceptives (birth control pills, patch, ring, injection)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Lamictal in the Treatment of Post-Herpetic Neuralgia | 临床试验